Clinical Outcomes Over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents With Severe Hemophilia A: Second Interim Analysis From the Phase 3 XTEND-ed Long-Term Extension Study

Oral presentation is available to registered attendees only via the ASH annual meeting virtual platform, as per congress regulations. 

Session Name: 322. Hemophilia A and B: Clinical and Epidemiological: Impact of Novel Therapies on Outcomes, Including Long-Term 

Session Date: Monday, December 9, 2024 

Session Time: 10:30 AM - 12:00 PM 

Presentation Time: 11:00 AM

Study funded by Sobi and Sanofi.

Link to Published Abstract